Skip to content
stoqly
en

Popular

All languages

Figures come from SEC filings, which are in English. Company and industry names stay as filed.

$ USD

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 23, 2026.

BGM Group Ltd.

BGM Nasdaq Pharmaceutical Preparations Financials FY2018โ€“FY2025

Revenue Total sales reported in the income statement.
$37.9M
51.1% vs prior year
Operating margin Operating income as a share of revenue.
โˆ’33.2%
30.9ย pts
Net income Profit after all expenses, interest and tax.
โˆ’$19.9M
Free cash flow Cash from operations minus capital spending.
โˆ’$3.9M
1,395.3%
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โ€”
Market cap Last close times the latest diluted share count, so it is approximate.
โ€”
P/E Last close divided by diluted earnings per share over the last four quarters.
โ€”
On โˆ’$0.18 EPS (TTM)

What BGM Group Ltd. does

No business description yet.

Legal name
BGM Group Ltd.
Fiscal year ends
September 30, 2025
Latest annual report
20-F ยท Jul 21, 2026
Accession ยท CIK
0001104659-26-085247
0001779578

Revenue and margins

BGM Group Ltd. had $37.9M of revenue in fiscal 2025, up 51.1% on the year before.

Revenue
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was โˆ’$3.9M in fiscal 2025, โˆ’10.4% of revenue. Cash from operations minus capital spending.

Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

BGM Group Ltd. returned โ€” to shareholders in fiscal 2025. The diluted share count rose 1,467.3%.

Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably BGM Group Ltd. can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $10.5M$14.3M$8.5M$9.8M$9.8M
Interest coverage 41.4xโ€”โ€”โ€”โ€”
Current ratio 2.2x3.3x5.2x3.4x1.2x
Quick ratio 1.5x2.3x4.4x2.8x0.8x
Total assets $75.4M$64.5M$51.3M$53.0M$434M
Total liabilities $18.7M$9.6M$6.9M$8.9M$41.9M
Shareholders' equity $54.9M$53.1M$42.8M$42.7M$391M
Net debt (โˆ’ = net cash) โ€”โ€”โ€”โ€”โ€”

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โ€œPlanโ€ marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

โ€”

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8โ€“9 is strong, 0โ€“2 weak.

TestFY18FY19FY20FY21FY22FY23FY24FY25
Net income is positive โœ“ โœ“ โœ“ โœ“ โœ“ โœ• โœ• โœ•
Cash from operations is positive โœ“ โœ• โœ“ โœ“ โœ“ โœ“ โœ“ โœ•
Return on assets rose โ€” โ€” โœ• โœ• โœ• โœ• โœ“ โœ•
Cash from operations exceeds net income โœ• โœ• โœ“ โœ• โœ“ โœ“ โœ“ โœ“
Debt fell relative to assets โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€”
Current ratio rose โ€” โ€” โœ• โœ“ โœ“ โœ“ โœ• โœ•
Share count didn't rise โ€” โœ“ โœ“ โœ• โœ“ โœ“ โœ“ โœ•
Gross margin rose โ€” โœ“ โœ• โœ• โœ• โœ• โœ“ โœ“
Revenue rose relative to assets โ€” โ€” โœ• โœ• โœ“ โœ• โœ• โœ•
F-score โ€” / 3โ€” / 54 / 83 / 86 / 84 / 85 / 82 / 8
Accruals ratio โ€”18.4%โˆ’0.0%4.5%โˆ’16.6%โˆ’14.0%โˆ’3.8%โˆ’7.2%
Altman Z'' โ€”6.015.525.868.9510.107.839.63

8 years of figures

Amounts in USD. Hover a ratioโ€™s name for its definition.

Download CSV
Fiscal yearFY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $50.4M $46.1M $50.0M $57.1M $64.9M $46.5M $25.1M $37.9M
Net interest income โ€” โ€” โˆ’$0.2M โˆ’$0.1M $0.0M $0.1M โ€” โ€”
Gross profit $8.1M $9.7M $7.5M $5.6M $6.2M $1.8M $4.1M $6.3M
Research and development โ€” $0.0M $0.1M $0.0M $1.2M $0.6M $1.4M $0.7M
Operating income $6.0M $6.2M $4.8M $2.4M $2.1M โˆ’$2.6M โˆ’$0.6M โˆ’$12.6M
Interest expense $0.2M $0.2M $0.2M $0.1M โ€” โ€” โ€” โ€”
Pretax income $6.1M $6.9M $5.8M $3.4M $1.6M โˆ’$7.9M โˆ’$2.1M โˆ’$19.9M
Income tax $0.9M $1.0M $0.9M $0.3M $0.2M $0.2M โˆ’$0.6M $0.3M
Net income $5.2M $5.9M $5.1M $3.2M $1.1M โˆ’$7.8M โˆ’$1.4M โˆ’$19.9M
Net income to common โ€” โ€” โ€” โ€” $1.1M โˆ’$7.8M โˆ’$1.4M โˆ’$19.9M
Diluted EPS $0.17 $0.18 $0.17 $0.09 $0.15 โˆ’$1.08 โˆ’$0.20 โˆ’$0.18
Diluted shares 0.03B 0.03B 0.03B 0.03B 0.01B 0.01B 0.01B 0.11B
Cash flow
Cash from operations $4.4M โˆ’$0.6M $5.1M $0.3M $12.7M $0.3M $0.5M โˆ’$2.4M
Capital expenditure $1.1M $0.6M $0.4M $1.5M $2.0M $0.2M $0.2M $1.6M
Free cash flow $3.3M โˆ’$1.2M $4.6M โˆ’$1.1M $10.6M $0.1M $0.3M โˆ’$3.9M
Depreciation and amortization $1.3M $1.2M $1.1M $1.2M $1.2M $1.1M $1.2M $1.5M
Stock-based compensation โ€” โ€” โ€” โ€” $0.0M โ€” โ€” $10.2M
Dividends paid $0.7M โ€” โ€” โ€” โ€” $1.8M โ€” โ€”
Dividends and buybacks $0.7M โ€” โ€” โ€” โ€” $1.8M โ€” โ€”
Balance sheet
Cash and short-term investments $5.6M $4.6M $11.9M $10.5M $14.3M $8.5M $9.8M $9.8M
Current assets โ€” $25.0M $37.5M $40.4M $30.0M $34.5M $29.8M $51.5M
Current liabilities โ€” $11.7M $18.4M $18.2M $9.2M $6.7M $8.8M $41.6M
Inventory โ€” $12.5M $12.0M $12.5M $8.9M $5.0M $5.0M $20.1M
Property and equipment, net โ€” $7.7M $7.4M $9.1M $10.2M โ€” โ€” โ€”
Goodwill โ€” โ€” โ€” โ€” โ€” โ€” โ€” $351M
Intangible assets โ€” $1.8M $1.9M $1.9M $1.7M $3.4M $4.5M $4.5M
Total assets โ€” $35.3M $48.1M $75.4M $64.5M $51.3M $53.0M $434M
Total liabilities โ€” $12.6M $19.3M $18.7M $9.6M $6.9M $8.9M $41.9M
Shareholders' equity $17.7M $19.9M $26.1M $54.9M $53.1M $42.8M $42.7M $391M
Margins
Gross margin 16.1% 21.0% 15.1% 9.9% 9.6% 3.8% 16.4% 16.6%
Operating margin 11.9% 13.4% 9.6% 4.2% 3.2% โˆ’5.6% โˆ’2.2% โˆ’33.2%
EBITDA margin 14.3% 16.0% 11.8% 6.3% 5.1% โˆ’3.2% 2.7% โˆ’29.3%
Net margin 10.3% 12.8% 10.1% 5.5% 1.7% โˆ’16.7% โˆ’5.7% โˆ’52.6%
FCF margin 6.6% โˆ’2.6% 9.2% โˆ’2.0% 16.4% 0.3% 1.2% โˆ’10.4%
Net interest share of revenue โ€” โ€” โˆ’0.5% โˆ’0.1% 0.0% 0.2% โ€” โ€”
Returns
Return on capital employed โ€” 26.2% 16.2% 4.2% 3.8% โˆ’5.9% โˆ’1.3% โˆ’3.2%
Return on equity 29.4% 31.4% 22.0% 7.8% 2.0% โˆ’16.2% โˆ’3.4% โˆ’9.2%
Return on assets โ€” 16.8% 12.1% 5.1% 1.5% โˆ’13.4% โˆ’2.8% โˆ’8.2%
Return on tangible equity 29.4% 32.7% 20.9% 6.0% 2.1% โˆ’19.8% โˆ’3.8% โˆ’56.1%
Growth
Revenue growth โ€” โˆ’8.5% 8.5% 14.1% 13.6% โˆ’28.3% โˆ’46.0% 51.1%
Net income growth โ€” 13.6% โˆ’14.3% โˆ’37.7% โˆ’65.9% โˆ’822.6% โ€” โ€”
EPS growth โ€” 5.9% โˆ’5.6% โˆ’47.1% 66.7% โˆ’820.0% โ€” โ€”
FCF growth โ€” โˆ’136.0% โ€” โˆ’124.8% โ€” โˆ’98.8% 129.7% โˆ’1,395.3%
Share count change โ€” 0.0% 0.0% 13.6% โˆ’78.8% 0.0% 0.0% 1,467.3%
Financial health
Interest coverage 27.6x 27.6x 19.8x 41.4x โ€” โ€” โ€” โ€”
Current ratio โ€” 2.1x 2.0x 2.2x 3.3x 5.2x 3.4x 1.2x
Quick ratio โ€” 1.1x 1.4x 1.5x 2.3x 4.4x 2.8x 0.8x
Capital allocation
Capex / revenue 2.2% 1.3% 0.9% 2.6% 3.1% 0.4% 1.0% 4.1%
Stock comp / revenue โ€” โ€” โ€” โ€” 0.0% โ€” โ€” 27.0%
Payouts / FCF 22.1% โ€” โ€” โ€” โ€” 1,350.1% โ€” โ€”
Quality scores
Piotroski F-score โ€” โ€” 4.0 3.0 6.0 4.0 5.0 2.0
Altman Z'' โ€” 6.0 5.5 5.9 8.9 10.1 7.8 9.6
Accruals ratio โ€” 18.4% โˆ’0.0% 4.5% โˆ’16.6% โˆ’14.0% โˆ’3.8% โˆ’7.2%

Source: SEC EDGAR XBRL filings (CIK 0001779578). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ€” not investment advice. Check the original filings before relying on any figure.

โ†‘ โ†“ to move ยท โ†ต to open